Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 1/2018

19.10.2017 | Rhinology

Effect of nasal antihistamine on secretory IgA in nasal lavage of rats

verfasst von: Remzi Doğan, Fadlullah Aksoy, Seda Sezen Goktas, Ilker Kocak, Yavuz Selim Yıldırım, Said Incir, Orhan Özturan

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

The humoral IgA is an immunoglobulin which plays a defensive role for organisms on mucosal surfaces. Today, intranasal antihistamines are effectively used in the treatment of allergic rhinitis. In our study, the effect of azelastine hydrochloride—a nasal antihistaminic—on humoral IgA of the nasal mucosa has been reviewed empirically. Twenty-four female Sprague–Dawley rats were included in our study. The rats were divided into three groups randomly. Group 1(azelastine hydrochloride): rats in this group had nasal azelastine hydrochloride (0.05%) applied for 30 days at 10 µl/nostril dosage. Group 2 (saline): saline (0.09%) was applied to the rats in this group for 30 days at 10 µl/nostril dosage. Group 3 (control): no application was made throughout the study. The chemicals applied in Groups 1 and 2 were applied to both nostrils by mounting a flexible micropipette to the end of an insulin injector. At the beginning of the study, nasal lavage was performed to both nostrils of the rats in every group on the 15th and 30th day to aspirate irrigation solution (distilled water). The aspirated liquids were kept at − 80° temperature and reviewed together at the end of study. Within-group comparisons: in Group 1 (azelastine hydrochloride), the humoral IgA value on the 15th day was significantly higher than the basal value (p = 0.037). There is a significant difference between humoral IgA value on the 30th day and humoral IgA value on the 15th day (p = 0.045). In Group 2 (saline), no significant difference is available between basal, 15th day and 30th day humoral IgA values (p = 0.265). In Group 3 (control), no significant difference is available between basal, 15th day and 30th day humoral IgA values (p = 0.374). Between-group comparison: there is no significant difference in between-group humoral IgA basal values (p = 0.714). On days 15 and 30, Humoral IgA value of Group 1 was significantly higher than that of Groups 2 and 3 (p = 0.013, p = 0.024, respectively). According to the results we achieved in our study, nasal antihistaminic (azelastine hydrochloride) significantly increases the level of humoral IgA. Our study is the first one in the literature to reveal a relation between nasal antihistaminic and humoral IgA and there is a further need for clinical, randomized and prospective studies.
Literatur
1.
Zurück zum Zitat Meltzer EO, Bukstein DA (2011) The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 106:12–16CrossRef Meltzer EO, Bukstein DA (2011) The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 106:12–16CrossRef
3.
Zurück zum Zitat Zechel HJ, Brock N, Lenke D, Achterrath-Tuckermann U (1981) Pharmacological and toxicological properties of azelastine, a novel antiallergic agent. Arzneimittelforschung 31:1184–1193PubMed Zechel HJ, Brock N, Lenke D, Achterrath-Tuckermann U (1981) Pharmacological and toxicological properties of azelastine, a novel antiallergic agent. Arzneimittelforschung 31:1184–1193PubMed
4.
Zurück zum Zitat LaForce C, Dockhorn RJ, Prenner BM, Chu TJ, Kraemer MJ, Widlitz MD et al (2004) Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 76:181–188CrossRef LaForce C, Dockhorn RJ, Prenner BM, Chu TJ, Kraemer MJ, Widlitz MD et al (2004) Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 76:181–188CrossRef
5.
Zurück zum Zitat Pilette C, Durham SR, Vaerman JP, Sibille Y (2004) Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc 1:125–135CrossRefPubMed Pilette C, Durham SR, Vaerman JP, Sibille Y (2004) Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc 1:125–135CrossRefPubMed
6.
Zurück zum Zitat Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25:5467–5484CrossRefPubMed Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25:5467–5484CrossRefPubMed
7.
Zurück zum Zitat Aksoy F, Dogan R, Kocak I, Veyseller B, Ozturan O, Incir S (2015) Effect of nasal corticosteroid on secretory immunoglobulin a measured in rat nasal lavage: experimental Study. Otolaryngol Head Neck Surg 153:298–301CrossRefPubMed Aksoy F, Dogan R, Kocak I, Veyseller B, Ozturan O, Incir S (2015) Effect of nasal corticosteroid on secretory immunoglobulin a measured in rat nasal lavage: experimental Study. Otolaryngol Head Neck Surg 153:298–301CrossRefPubMed
8.
Zurück zum Zitat LaForce CF, Corren J, Wheeler WJ, Berger WE, Rhinitis Study Group (2004) Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol 93:154–159CrossRefPubMed LaForce CF, Corren J, Wheeler WJ, Berger WE, Rhinitis Study Group (2004) Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol 93:154–159CrossRefPubMed
9.
Zurück zum Zitat Horak F, Zieglmayer UP, Zieglmayer R et al (2006) Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin 22:151–157CrossRefPubMed Horak F, Zieglmayer UP, Zieglmayer R et al (2006) Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin 22:151–157CrossRefPubMed
10.
Zurück zum Zitat Davies RJ, Bagnall AC, McCabe RN, Calderon MA, Wang JH (1996) Antihistamines: topical vs oral administration. Clin Exp Allergy 26:11–17CrossRefPubMed Davies RJ, Bagnall AC, McCabe RN, Calderon MA, Wang JH (1996) Antihistamines: topical vs oral administration. Clin Exp Allergy 26:11–17CrossRefPubMed
11.
Zurück zum Zitat Woof JM, Russell MW (2011) Structure and function relationships in IgA. Mucosal Immunol 4:590–597CrossRefPubMed Woof JM, Russell MW (2011) Structure and function relationships in IgA. Mucosal Immunol 4:590–597CrossRefPubMed
12.
Zurück zum Zitat Rochereau N, Pavot V, Verrier B, Jospin F, Ensinas A, Genin C et al (2016) Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity. J Allergy Clin Immunol. 137:214–222CrossRefPubMed Rochereau N, Pavot V, Verrier B, Jospin F, Ensinas A, Genin C et al (2016) Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity. J Allergy Clin Immunol. 137:214–222CrossRefPubMed
13.
Zurück zum Zitat Corthésy B (2010) Role of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces. Future Microbiol. 5:817–829CrossRefPubMed Corthésy B (2010) Role of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces. Future Microbiol. 5:817–829CrossRefPubMed
14.
Zurück zum Zitat Corthésy B (2013) Role of secretory IgA in infection and maintenance of homeostasis. Autoimmun Rev 12:661–665CrossRefPubMed Corthésy B (2013) Role of secretory IgA in infection and maintenance of homeostasis. Autoimmun Rev 12:661–665CrossRefPubMed
15.
Zurück zum Zitat Peebles RS, Liu MC, Lichtenstein LM, Hamilton RG (1995) IgA, IgG and IgM quantification in bronchoalveolar lavage fluids from allergic rhinitis, allergic asthmatics, and normal subjects by mAb-based immunoenzymetric assays. J Immunol Methods 179:77CrossRefPubMed Peebles RS, Liu MC, Lichtenstein LM, Hamilton RG (1995) IgA, IgG and IgM quantification in bronchoalveolar lavage fluids from allergic rhinitis, allergic asthmatics, and normal subjects by mAb-based immunoenzymetric assays. J Immunol Methods 179:77CrossRefPubMed
16.
Zurück zum Zitat Nahm DH, Park HS (1997) Correlation between IgA antibody and eosinophil cationic protein levels in induced sputum from asthmatic patients. Clin Exp Allergy 27:676CrossRefPubMed Nahm DH, Park HS (1997) Correlation between IgA antibody and eosinophil cationic protein levels in induced sputum from asthmatic patients. Clin Exp Allergy 27:676CrossRefPubMed
18.
Zurück zum Zitat Fagerås M, Tomičić S, Voor T, Björkstén B, Jenmalm MC (2011) Slow salivary secretory IgA maturation may relate to low microbial pressure and allergic symptoms in sensitized children. Pediatr Res 70:572–577CrossRefPubMed Fagerås M, Tomičić S, Voor T, Björkstén B, Jenmalm MC (2011) Slow salivary secretory IgA maturation may relate to low microbial pressure and allergic symptoms in sensitized children. Pediatr Res 70:572–577CrossRefPubMed
19.
Zurück zum Zitat Balzar S, Strand M, Nakano T, Wenzel SE (2006) Subtle immunodeficiency in severe asthma: IgA and IgG2 correlate with lung function and symptoms. Int Arch Allergy Immunol 140:96–102CrossRefPubMed Balzar S, Strand M, Nakano T, Wenzel SE (2006) Subtle immunodeficiency in severe asthma: IgA and IgG2 correlate with lung function and symptoms. Int Arch Allergy Immunol 140:96–102CrossRefPubMed
20.
Zurück zum Zitat Hamasaki Y, Shafigeh M, Yamamoto S, Sato R, Zaitu M, Muro E et al (1996) Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol 76:469–475CrossRefPubMed Hamasaki Y, Shafigeh M, Yamamoto S, Sato R, Zaitu M, Muro E et al (1996) Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol 76:469–475CrossRefPubMed
21.
Zurück zum Zitat Shin MH, Baroody F, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM (1992) The effect of azelastine on the early allergic response. Clin Exp Allergy 22:289–295CrossRefPubMed Shin MH, Baroody F, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM (1992) The effect of azelastine on the early allergic response. Clin Exp Allergy 22:289–295CrossRefPubMed
22.
Zurück zum Zitat Busse W, Randlev B, Sedgwick J (1989) The effect of azelastine on neutrophil and eosinophil generation of superoxide. J Allergy Clin Immunol. 83:400–405CrossRefPubMed Busse W, Randlev B, Sedgwick J (1989) The effect of azelastine on neutrophil and eosinophil generation of superoxide. J Allergy Clin Immunol. 83:400–405CrossRefPubMed
23.
Zurück zum Zitat Yoneda K, Yamamoto T, Ueta E, Osaki T (1997) Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 73:145–153CrossRefPubMed Yoneda K, Yamamoto T, Ueta E, Osaki T (1997) Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 73:145–153CrossRefPubMed
24.
Zurück zum Zitat Ciprandi G, Pronzato C, Passalacqua G, Ricca V, Grögen J, Mela GS et al (1996) Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol. 98:1088–1096CrossRefPubMed Ciprandi G, Pronzato C, Passalacqua G, Ricca V, Grögen J, Mela GS et al (1996) Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol. 98:1088–1096CrossRefPubMed
25.
Zurück zum Zitat Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR et al (2015) Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg 152:1–43CrossRef Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR et al (2015) Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg 152:1–43CrossRef
26.
Zurück zum Zitat Bernstein JA (2007) Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin 23:2441–2452CrossRefPubMed Bernstein JA (2007) Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin 23:2441–2452CrossRefPubMed
27.
Zurück zum Zitat Lee TA, Pickard AS (2007) Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy. 27:852–859CrossRefPubMed Lee TA, Pickard AS (2007) Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy. 27:852–859CrossRefPubMed
28.
Zurück zum Zitat Iikura M, Yamaguchi M, Fujisawa T et al (1998) Secretory IgA induces degranulation of IL-3-primed basophils. J Immunol 161(3):1510–1515PubMed Iikura M, Yamaguchi M, Fujisawa T et al (1998) Secretory IgA induces degranulation of IL-3-primed basophils. J Immunol 161(3):1510–1515PubMed
29.
Zurück zum Zitat Iikura M, Yamaguchi M, Miyamasu M et al (1999) Secretory IgA-mediated basophil activation. II. Roles of GTP-binding regulatory proteins and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 264(2):575–579CrossRefPubMed Iikura M, Yamaguchi M, Miyamasu M et al (1999) Secretory IgA-mediated basophil activation. II. Roles of GTP-binding regulatory proteins and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 264(2):575–579CrossRefPubMed
30.
Zurück zum Zitat Dilek F, Ozkaya E, Gultepe B, Yazici M, Iraz M (2016) Nasal fluid secretory immunoglobulin A levels in children with allergic rhinitis. Int J Pediatr Otorhinolaryngol 83:41–46CrossRefPubMed Dilek F, Ozkaya E, Gultepe B, Yazici M, Iraz M (2016) Nasal fluid secretory immunoglobulin A levels in children with allergic rhinitis. Int J Pediatr Otorhinolaryngol 83:41–46CrossRefPubMed
31.
Zurück zum Zitat Hsin C-H, Shun C-T, Liu C-M (2008) Immunoglobulins in nasal secretions of patients with allergic rhinitis and chronic rhinosinusitis. Eur Arch Oto-Rhino-Laryngol 265:539–542CrossRef Hsin C-H, Shun C-T, Liu C-M (2008) Immunoglobulins in nasal secretions of patients with allergic rhinitis and chronic rhinosinusitis. Eur Arch Oto-Rhino-Laryngol 265:539–542CrossRef
32.
Zurück zum Zitat Cortesina G, Carlevato MT, Bussi M, Baldi C, Majore L, Ruffino C (1993) Mucosal immunity in allergic rhinitis. Acta Otolaryngol 113:397–399CrossRefPubMed Cortesina G, Carlevato MT, Bussi M, Baldi C, Majore L, Ruffino C (1993) Mucosal immunity in allergic rhinitis. Acta Otolaryngol 113:397–399CrossRefPubMed
33.
Zurück zum Zitat Kita H, Jorgensen RK, Reed CE et al (2000) Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6, and IgE antibody production are unaffected. J Allergy Clin Immunol. 106:521–529CrossRefPubMed Kita H, Jorgensen RK, Reed CE et al (2000) Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6, and IgE antibody production are unaffected. J Allergy Clin Immunol. 106:521–529CrossRefPubMed
34.
Zurück zum Zitat Benson M, Reinholdt J, Cardell LO (2004) No decrease of birch pollen specific IgA and IgG in nasal fluids from cortisone treated patients with intermittent allergic rhinitis. Allergy 59:365–367CrossRefPubMed Benson M, Reinholdt J, Cardell LO (2004) No decrease of birch pollen specific IgA and IgG in nasal fluids from cortisone treated patients with intermittent allergic rhinitis. Allergy 59:365–367CrossRefPubMed
Metadaten
Titel
Effect of nasal antihistamine on secretory IgA in nasal lavage of rats
verfasst von
Remzi Doğan
Fadlullah Aksoy
Seda Sezen Goktas
Ilker Kocak
Yavuz Selim Yıldırım
Said Incir
Orhan Özturan
Publikationsdatum
19.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 1/2018
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-017-4750-1

Weitere Artikel der Ausgabe 1/2018

European Archives of Oto-Rhino-Laryngology 1/2018 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.